Isis Pharmaceuticals (ISIS +0.6%) says it's triggered a $7.5M milestone payment from...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS +0.6%) says it's triggered a $7.5M milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study for ISIS-TTR, an antisense drug for treating transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.